JP2022554277A5 - - Google Patents

Info

Publication number
JP2022554277A5
JP2022554277A5 JP2022525291A JP2022525291A JP2022554277A5 JP 2022554277 A5 JP2022554277 A5 JP 2022554277A5 JP 2022525291 A JP2022525291 A JP 2022525291A JP 2022525291 A JP2022525291 A JP 2022525291A JP 2022554277 A5 JP2022554277 A5 JP 2022554277A5
Authority
JP
Japan
Prior art keywords
composition according
composition
reduction
treatment
determined
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022525291A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022554277A (ja
JP7664239B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/058411 external-priority patent/WO2021087399A1/en
Publication of JP2022554277A publication Critical patent/JP2022554277A/ja
Publication of JP2022554277A5 publication Critical patent/JP2022554277A5/ja
Priority to JP2025063020A priority Critical patent/JP2025106418A/ja
Application granted granted Critical
Publication of JP7664239B2 publication Critical patent/JP7664239B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022525291A 2019-10-30 2020-10-30 エンドセリンレセプターアンタゴニストを使用する眼疾患の処置 Active JP7664239B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025063020A JP2025106418A (ja) 2019-10-30 2025-04-07 エンドセリンレセプターアンタゴニストを使用する眼疾患の処置

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962928092P 2019-10-30 2019-10-30
US62/928,092 2019-10-30
US202063068215P 2020-08-20 2020-08-20
US63/068,215 2020-08-20
PCT/US2020/058411 WO2021087399A1 (en) 2019-10-30 2020-10-30 Treatment of ocular diseases using endothelin receptor antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025063020A Division JP2025106418A (ja) 2019-10-30 2025-04-07 エンドセリンレセプターアンタゴニストを使用する眼疾患の処置

Publications (3)

Publication Number Publication Date
JP2022554277A JP2022554277A (ja) 2022-12-28
JP2022554277A5 true JP2022554277A5 (cg-RX-API-DMAC7.html) 2023-11-07
JP7664239B2 JP7664239B2 (ja) 2025-04-17

Family

ID=75715356

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022525291A Active JP7664239B2 (ja) 2019-10-30 2020-10-30 エンドセリンレセプターアンタゴニストを使用する眼疾患の処置
JP2025063020A Pending JP2025106418A (ja) 2019-10-30 2025-04-07 エンドセリンレセプターアンタゴニストを使用する眼疾患の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025063020A Pending JP2025106418A (ja) 2019-10-30 2025-04-07 エンドセリンレセプターアンタゴニストを使用する眼疾患の処置

Country Status (9)

Country Link
US (5) US11738007B2 (cg-RX-API-DMAC7.html)
EP (2) EP4094759A1 (cg-RX-API-DMAC7.html)
JP (2) JP7664239B2 (cg-RX-API-DMAC7.html)
CN (2) CN118203574A (cg-RX-API-DMAC7.html)
AU (1) AU2020373065A1 (cg-RX-API-DMAC7.html)
CA (1) CA3158767A1 (cg-RX-API-DMAC7.html)
IL (1) IL292350A (cg-RX-API-DMAC7.html)
MX (1) MX2022005063A (cg-RX-API-DMAC7.html)
WO (1) WO2021087399A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
JP7664239B2 (ja) 2019-10-30 2025-04-17 パフューズ セラピューティクス, インコーポレイテッド エンドセリンレセプターアンタゴニストを使用する眼疾患の処置
CA3168810A1 (en) 2020-02-06 2021-08-12 Perfuse Therapeutics, Inc. Compositions for treatment of ocular diseases
BR112023022705A2 (pt) * 2021-04-30 2024-01-16 Perfuse Therapeutics Inc Composições farmacêuticas e sistemas de entrega intravítrea de fármacos para o tratamento de doenças oculares
CN117295520A (zh) * 2021-04-30 2023-12-26 珀弗斯治疗股份有限公司 使用内皮素受体拮抗剂治疗眼部疾病
WO2022251710A2 (en) 2021-05-28 2022-12-01 Sight Sciences, Inc. Intraocular devices, systems, and methods
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4282793A (en) * 1992-04-10 1993-11-18 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University A microneedle for injection of ocular blood vessels
US6162927A (en) 1994-08-19 2000-12-19 Abbott Laboratories Endothelin antagonists
JPH0959173A (ja) * 1995-08-21 1997-03-04 Santen Pharmaceut Co Ltd 毛様体筋緊張緩和剤
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
CZ20032350A3 (en) * 2001-02-02 2004-03-17 Merck Patent Gmbh PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO 4,3-d PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS
US20030176356A1 (en) * 2001-04-24 2003-09-18 University Of North Texas Health Science Center Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma
GB0122318D0 (en) * 2001-09-14 2001-11-07 Novartis Ag Organic compounds
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US20070260203A1 (en) 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
CA2697057A1 (en) 2007-08-22 2009-02-26 Gilead Colorado, Inc. Therapy for complications of diabetes
PL2424530T3 (pl) 2009-04-30 2016-07-29 Univ Midwestern Sposób i kompozycja do leczenia cukrzycowej kwasicy ketonowej
US20110082151A1 (en) 2009-06-12 2011-04-07 Auspex Pharmaceuticals, Inc. Sulfonylurea modulators of endothelin receptor
AR080888A1 (es) 2010-04-12 2012-05-16 R Tech Ueno Ltd Uso de un derivado de acido graso para producir una composicion oftalmica
ES2813383T3 (es) * 2013-12-19 2021-03-23 Tassos Georgiou Composición de ácidos grasos omega 3 para tratar enfermedades que implican daños en el sistema nervioso
ES2584534B1 (es) 2015-03-27 2017-03-13 Retinset, S.L. Formulación tópica oftálmica de bosentan
JP2018522942A (ja) * 2015-05-29 2018-08-16 エッジ セラピューティクス インコーポレイテッド 視力障害を低減するための組成物及び方法
WO2017217967A1 (en) * 2016-06-13 2017-12-21 Noveome Biotherapeutics, Inc. Novel methods for delivering therapeutic agents to the eye via nasal passages
WO2018185516A1 (en) 2017-04-05 2018-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
US11286274B2 (en) * 2017-06-19 2022-03-29 Mitopower Llc Nicotinamide riboside derivatives and their uses
US10905770B2 (en) * 2017-07-17 2021-02-02 Macregen, Inc. Topical delivery of therapeutic agents using cell-penetrating peptides for the treatment of age-related macular degeneration and other eye diseases
WO2019210194A1 (en) * 2018-04-26 2019-10-31 Vitrisa Therapeutics, Inc. Pegylated compositions for ocular use, and methods thereof
JP7664239B2 (ja) 2019-10-30 2025-04-17 パフューズ セラピューティクス, インコーポレイテッド エンドセリンレセプターアンタゴニストを使用する眼疾患の処置
CA3168810A1 (en) * 2020-02-06 2021-08-12 Perfuse Therapeutics, Inc. Compositions for treatment of ocular diseases
BR112023022705A2 (pt) 2021-04-30 2024-01-16 Perfuse Therapeutics Inc Composições farmacêuticas e sistemas de entrega intravítrea de fármacos para o tratamento de doenças oculares

Similar Documents

Publication Publication Date Title
Casson Medical therapy for glaucoma: A review
Soltau et al. Changing paradigms in the medical treatment of glaucoma
JP6014033B2 (ja) 防腐剤無添加ビマトプロストおよびチモロール溶液
US10213431B2 (en) Preservative free brimonidine and timolol solutions
US20060111388A1 (en) Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye
IL292350A (en) Treatment of ocular diseases using endothelin receptor antagonists
Schellack et al. Glaucoma: a brief review
Ha et al. Sovesudil (locally acting rho kinase inhibitor) for the treatment of normal‐tension glaucoma: the randomized phase II study
ES2210018T3 (es) Antagonistas de 5ht-2 para regular la presion intraocular y tratar el glaucoma.
Miller-Ellis et al. Then and now: medical therapy for glaucoma
Weinreb et al. Latanoprostene bunod, a dual-acting nitric oxide donating prostaglandin analog for lowering of intraocular pressure
US7638516B2 (en) Agent for therapeutic treatment of optic nerve diseases and the like
WO2019024433A1 (zh) 氨基金刚烷胺单硝酸酯类化合物眼用组合物及其制剂和应用
WO2003004058A1 (fr) Agents de protection du nerf optique contenant un bloqueur de recepteur $g(a)1 en tant qu'ingredient actif
CN115998888A (zh) 用于治疗青光眼或高眼压症的药物组合物及其用途
JP2024516829A5 (cg-RX-API-DMAC7.html)
Higginbotham Will latanoprost be the'wonder'drug of the'90s for the treatment of glaucoma?
US5563171A (en) Treatment of glaucoma and ocular hypertension with β3-adrenergic agonists
Kim et al. Medical Treatment of Glaucoma
KR20030063387A (ko) 망막 허혈에 기초하는 질환의 치료 및/또는 예방제
Kanner et al. Adrenergic Agents
Realini et al. 19. The History of Glaucoma Medications
Dada et al. Medical Management of Glaucoma
Tab Peridex, PerioGard Oral soln: 0.12%(480ml)
ALI Medical Management of Glaucoma